Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478240 | 0.86 | PTGS2 (0.56) | PTGS2PTGS1GSK3BPKM | |
| SCHEMBL4471819 | 0.84 | PTGS2 (0.52) | PTGS2PTGS1GSK3BPKM | |
| SCHEMBL4480066 | 0.83 | GSK3B (0.44) | PTGS2PTGS1GSK3BPKM | |
| SCHEMBL4482399 | 0.82 | ALDH1A1 (0.42) | PTGS2TRPV1PTGS1GSK3B | |
| SCHEMBL4482406 | 0.82 | ALDH1A1 (0.42) | PTGS2TRPV1PTGS1GSK3B | |
| SCHEMBL4474537 | 0.81 | PTGS2 (0.41) | PTGS2TRPV1PTGS1GSK3BPTGER1 | |
| SCHEMBL4472139 | 0.81 | PTGS1 (0.58) | PTGS2PTGS1GSK3BPTGER1 | |
| SCHEMBL4478445 | 0.72 | DYRK1A (0.43) | PTGS2 | |
| SCHEMBL17295125 | 0.72 | SCN9A (0.44) | GSK3B | |
| SCHEMBL17290240 | 0.72 | SCN9A (0.44) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | PTGS2 4182/4885TRPV1 4489/4885PTGS1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.